Analyst firms · BofA Securities · OSCR
BofA Securities OSCR price target and rating history
Oscar Health Inc. (OSCR) · Health Care
BofA Securities rates Oscar Health Inc. (OSCR) Underperform with a $13.50 price target, as of its latest action on Nov 6, 2024. It has published 6 rating actions on OSCR since May 2022, including 2 upgrades and 4 downgrades. Across 7 firms with a OSCR price target in the last 12 months, the median target is $18.
- Current rating
- Underperform
- Price target
- $13.50
- Median target, all firms
- $18
- Actions on OSCR
- 6
BofA Securities price target on OSCR
Every BofA Securities rating on OSCR
- Nov 6, 2024
- May 30, 2024
- Nov 2, 2023
- Jun 6, 2023
- Jun 15, 2022
- May 26, 2022
How other firms rate OSCR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $35 | Jun 10, 2026 |
| Wells Fargo | Equal Weight | $20 | Jun 4, 2026 |
| Wolfe Research | Peer Perform | May 6, 2026 | |
| Jefferies | Hold | $16 | Apr 20, 2026 |
| Raymond James | Outperform | $18 | Feb 12, 2026 |
| UBS | Neutral | $17 | Jan 9, 2026 |
| Stephens | Equal-Weight | $17 | Dec 11, 2025 |
| Piper Sandler | Overweight | $25 | Nov 26, 2025 |
Questions about BofA Securities and OSCR
- What is BofA Securities's price target for OSCR?
- BofA Securities's latest stated price target for Oscar Health Inc. (OSCR) is $13.50, from its action on Nov 6, 2024.
- What is BofA Securities's rating on OSCR?
- BofA Securities rates OSCR Underperform, a bearish rating, as of Nov 6, 2024.
- When did BofA Securities last change its view on OSCR?
- On Nov 6, 2024, BofA Securities downgrades to Underperform from Neutral, price target $21 to $13.50.
- How does BofA Securities's OSCR target compare with other analysts?
- Across 7 firms with a OSCR price target in the last 12 months, the median target is $18.
More OSCR rating histories
All BofA Securities ratingsOSCR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.